カテゴリー： 世界, 医療/バイオ, visiongain

世界の喘息＆COPD治療市場2023年～2033年

【英語タイトル】Asthma & COPD Therapies Market Report 2023-2033 : Forecasts by Product (Anti-inflammatory Drugs, Bronchodilators Monotherapy, Combination Drugs), by Route of Administration (Oral, Inhaled, Others), by Point of Sale (Retail Pharmacies, Hospital Pharmacies, Others) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Impact and Recovery Pattern Analysis

visiongainが出版した調査資料（VGA23FB019）・商品コード：VGA23FB019
・発行会社（調査会社）：visiongain
・発行日：2023年1月3日
・ページ数：248
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後24時間以内）
・調査対象地域：グローバル
・産業分野：医薬品
◆販売価格オプション（消費税別）
Sigle User（1名様閲覧用、1年間、印刷不可）GBP3,950 ⇒換算￥750,500見積依頼/購入/質問フォーム
Enterprise（法人閲覧用、1年間、印刷可）GBP6,950 ⇒換算￥1,320,500見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
❖ レポートの概要 ❖

Visiongain社の本調査レポートでは、世界の喘息＆COPD治療市場規模が2033年までに年平均7.31%で成長すると予測しています。本レポートは、喘息＆COPD治療の世界市場を徹底調査し、レポート概要、エグゼクティブサマリー、イントロダクション、市場動向、製品別（抗炎症薬、気管支拡張薬、併用薬）分析、投与経路別（経口、吸入、その他）分析、PoS別（小売薬局、病院薬局、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、企業情報などの内容を作成しました。本書には、AstraZeneca、Boehringer Ingelheim、Chiesi Farmaceutici S.p.A.、Cipla Inc.、F. Hoffmann-La Roche Ltd.、Grifols S.A.、GSK plc、Mundipharma、Novartis AG、Pulmatrix、Respiratorius AB、Sanofi SA、Sunovion Pharmaceuticals Inc.などの企業情報が含まれています。
・レポート概要
・エグゼクティブサマリー
・イントロダクション
・市場動向
・世界の喘息＆COPD治療市場規模：製品別
- 抗炎症薬の市場規模
- 気管支拡張薬の市場規模
- 併用薬の市場規模
・世界の喘息＆COPD治療市場規模：投与経路別
- 経口用治療薬の市場規模
- 吸入用治療薬の市場規模
- その他治療薬の市場規模
・世界の喘息＆COPD治療市場規模：PoS別
- 小売薬局チャネルの市場規模
- 病院薬局チャネルの市場規模
- その他チャネルの市場規模
・世界の喘息＆COPD治療市場規模：地域別
- 北米の喘息＆COPD治療市場規模
- ヨーロッパの喘息＆COPD治療市場規模
- アジア太平洋の喘息＆COPD治療市場規模
- 中南米の喘息＆COPD治療市場規模
- 中東・アフリカの喘息＆COPD治療市場規模
・企業情報

The Asthma & COPD Therapies Market Report 2023-2033: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Expansion into Emerging Markets to Offer Lucrative Growth Opportunities
For the overall asthma and COPD market, expansion into the emerging markets will be of high importance in the years to come, in particular as the US and European markets become saturated and experience slow growth or decline due to patent expiry, generic competition and low healthcare budgets. The economic troubles currently being experienced in a number of emerging markets are likely to lift over the next ten years, returning those nations to continued expansion of their healthcare systems and satisfaction of unmet treatment needs. Inhaled drugs will continue to be less affected by patent expiries, as long as the inhaler patents are intact. Advances in inhaler design will continue to be of vital importance to the market.

Nevertheless, the asthma and COPD market have a potential for a number of blockbuster drugs with increasingly segmented sub-groups of patients. The market also benefits from increasing prevalence of respiratory diseases, coupled with the high economic cost of those diseases, revenues are expected to increase in the years to come. New combination drugs will drive growth. The industry will also have more biologics and synthetic anti-inflammatory agents for both asthma and COPD, as companies look to identify and offer treatments for multiple patient sub-groups. Future success will on long-term planning, to maximise the revenues for existing drugs (life cycle management), to successfully expand into emerging markets and to identify and address unmet needs in the patient population depend on novel and effective therapies.

What Questions Should You Ask before Buying a Market Research Report?
• How is the asthma & COPD therapies market evolving?
• What is driving and restraining the asthma & COPD therapies market?
• How will each asthma & COPD therapies submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2033?
• How will the market shares for each asthma & COPD therapies submarket develop from 2023 to 2033?
• What will be the main driver for the overall market from 2023 to 2033?
• Will leading asthma & COPD therapies markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2033 and which geographical region will lead the market in 2033?
• Who are the leading players and what are their prospects over the forecast period?
• What are the asthma & COPD therapies projects for these leading companies?
• How will the industry evolve during the period between 2023 and 2033? What are the implications of
asthma & COPD therapies projects taking place now and over the next 10 years?
• Is there a greater need for product commercialisation to further scale the asthma & COPD therapies market?
• Where is the asthma & COPD therapies market heading and how can you ensure you are at the forefront of the market?
• What are the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the asthma & COPD therapies market today, and over the next 10 years:
• Our 248-page report provides 107 tables and 130 charts/graphs exclusively to you.
• The report highlights key lucrative areas in the industry so you can target them – NOW.
• It contains in-depth analysis of global, regional and national sales and growth.
• It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the asthma & COPD therapies market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2033 and other analyses reveal commercial prospects
• In addition to revenue forecasting to 2033, our new study provides you with recent results, growth rates, and market shares.
• You will find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, and restraints), Porter’s Five Forces Analysis, PEST Analysis and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.

Segments Covered in the Report

Product
• Anti-inflammatory Drugs
• Bronchodilators Monotherapy
• Combination Drugs

Route of Administration
• Oral
• Inhaled
• Others

Point of Sale
• Retail Pharmacies
• Hospital Pharmacies
• Others

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 20 leading national markets:

North America
• U.S.
• Canada

Europe
• Germany
• UK
• France
• Italy
• Spain
• Rest of Europe

Asia Pacific
• Japan
• China
• India
• Australia
• South Korea
• Rest of Asia Pacific

Latin America
• Brazil
• Mexico
• Rest of Latin America

MEA
• GCC
• South Africa
• Rest of MEA

The report also includes profiles and for some of the leading companies in the Asthma & COPD Therapies Market, 2023 to 2033, with a focus on this segment of these companies’ operations.

Leading companies and the potential for market growth
• AstraZeneca
• Boehringer Ingelheim
• Chiesi Farmaceutici S.p.A.
• Cipla Inc.
• F. Hoffmann-La Roche Ltd.
• Grifols S.A.
• GSK plc
• Mundipharma
• Novartis AG
• Pulmatrix
• Respiratorius AB
• Sanofi SA
• Sunovion Pharmaceuticals Inc.
• Teva Pharmaceutical Industries Ltd.
• TFF Pharmaceuticals, Inc.
• Transpire Bio
• Verona Pharma plc
• Viatris Inc.

Overall world revenue for Asthma & COPD Therapies Market, 2023 to 2033 in terms of value the market will surpass US$47 billion in 2023, our work calculates. We predict strong revenue growth through to 2033. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Asthma & COPD Therapies Market, 2023 to 2033 report help you?
In summary, our 240+ page report provides you with the following knowledge:

• Revenue forecasts to 2033 for Asthma & COPD Therapies Market, 2023 to 2033 Market, with forecasts for Product, Route of Administration, and Point of Sale, each forecast at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues.

• Revenue forecasts to 2033 for five regional and 20 key national markets – See forecasts for the Asthma & COPD Therapies Market, 2023 to 2033 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.

• Prospects for established firms and those seeking to enter the market – including company profiles for 18 of the major companies involved in the Asthma & COPD Therapies Market, 2023 to 2033.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else
With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Our study is for everybody needing commercial analyses for the Asthma & COPD Therapies Market, 2023 to 2033, market-leading companies. You will find data, trends and predictions.

グローバル市場調査レポート販売サイトのwww.marketreport.jpです。

❖ レポートの目次 ❖

1. Report Overview
1.1 Objectives of the Study
1.2 Introduction to Asthma & COPD Therapies Market
1.3 What This Report Delivers
1.4 Why You Should Read This Report
1.5 Key Questions Answered by This Analytical Report Include:
1.6 Who is This Report For?
1.7 Methodology
1.7.1 Market Definitions
1.7.2 Market Evaluation & Forecasting Methodology
1.7.3 Data Validation
1.7.3.1 Primary Research
1.7.3.2 Secondary Research
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Reports
1.10 About

2 Executive Summary

3 Introduction to the COPD and Asthma Therapies Market
3.1 Introduction to the COPD and Asthma Therapies
3.2 The Pharmaceutical Industry: A Very Brief Overview
3.3 What is Asthma?
3.3.1 Trends in Asthma Prevalence
3.3.2 Pathophysiology of Asthma
3.3.3 Symptoms of Asthma
3.3.4 Causes and Triggers for Asthma
3.3.5 Treatment of Asthma
3.3.6 Drug Delivery Methods in Asthma
3.4 What is Chronic Obstructive Pulmonary Disease (COPD)?
3.4.1 Trends in COPD Prevalence
3.4.2 Pathophysiology of COPD
3.4.3 Signs and Symptoms of COPD
3.4.4 Treatment of COPD
3.4.5 Drug Treatments for COPD
3.4.6 Guidelines for COPD Treatment
3.5 Major Drug Classes in the Treatment of Asthma and COPD
3.5.1 Bronchodilators
3.5.1.1 Beta2-Agonists
3.5.1.2 Anticholinergics
3.5.2 Anti-Inflammatory Drugs
3.5.2.1 Corticosteroids
3.5.2.2 Leukotriene Receptor Antagonists
3.5.2.3 Monoclonal Antibodies in the Treatment of Respiratory Disease
3.5.3 Combination Drugs

4 Market Overview
4.1 Key Findings
4.2 Market Dynamics
4.2.1 Market Driving Factors
4.2.2 Increasing Prevalence of Respiratory Diseases on Account of Increasing Pollution
4.2.3 Reducing Social Stigma Asthma and COPD
4.2.4 Strong Pipeline for Asthma Drugs
4.3 Market Restraints
4.4 Market Opportunities
4.4.1 Telehealth
4.5 Porter’s Five Forces
4.5.1 Bargaining Power of Buyers
4.5.2 Bargaining Power of Suppliers
4.5.3 Threat of Substitutes
4.5.4 Threat of New Entrants
4.5.5 Industry Rivalry
4.6 SWOT Analysis
4.7 COVID-19 Impact Analysis

5 Asthma & COPD Therapies Market Analysis by Product
5.1 Key Findings
5.2 Product Segment: Market Attractiveness Index
5.3 Asthma & COPD Therapies Market Size Estimation and Forecast by Product
5.4 Anti-inflammatory Drugs
5.4.1 Anti-inflammatory Drugs Submarket Forecast by Type, 2023-2033 (US$ bn)
5.5 Bronchodilators Monotherapy
5.5.1 Bronchodilators Monotherapy Submarket Forecast by Type, 2023-2033 (US$ bn)
5.6 Combination Drugs
5.6.1 Combination Drugs Submarket Forecast by Type, 2023-2033 (US$ bn)

6 Asthma & COPD Therapies Market Analysis by Route of Administration
6.1 Key Findings
6.2 Route of Administration Segment: Market Attractiveness Index
6.3 Asthma & COPD Therapies Market Size Estimation and Forecast by Route of Administration
6.4 Oral
6.4.1 Market Forecast by Region, 2023-2033 (US$ bn)
6.4.2 Market Share by Region, 2023 & 2033 (%)
6.5 Inhaled
6.5.1 Market Forecast by Region, 2023-2033 (US$ bn)
6.5.2 Market Share by Region, 2023 & 2033 (%)
6.6 Others
6.6.1 Market Forecast by Region, 2023-2033 (US$ bn)
6.6.2 Market Share by Region, 2023 & 2033 (%)

7 Asthma & COPD Therapies Market Analysis by Point of Sale
7.1 Key Findings
7.2 Point of Sale Segment: Market Attractiveness Index
7.3 Asthma & COPD Therapies Market Size Estimation and Forecast by Point of Sale
7.4 Retail Pharmacies
7.4.1 Market Forecast by Region, 2023-2033 (US$ bn)
7.4.2 Market Share by Region, 2023 & 2033 (%)
7.5 Hospital Pharmacies
7.5.1 Market Forecast by Region, 2023-2033 (US$ bn)
7.5.2 Market Share by Region, 2023 & 2033 (%)
7.6 Others
7.6.1 Market Forecast by Region, 2023-2033 (US$ bn)
7.6.2 Market Share by Region, 2023 & 2033 (%)

8 Asthma & COPD Therapies Market Analysis by Region
8.1 Key Findings
8.2 Regional Market Size Estimation and Forecast

9 North America Asthma & COPD Therapies Market Analysis
9.1 Key Findings
9.2 North America Asthma & COPD Therapies Market Attractiveness Index
9.3 Market Size by Country, 2023, 2028 & 2033 (US$ Bn)
9.4 Market Size Estimation and Forecast by Country, 2023-2033 (US$ bn)
9.5 Market Size Estimation and Forecast by Route of Administration, 2023-2033 (US$ bn)
9.6 Market Size Estimation and Forecast by Point of Sale, 2023-2033 (US$ bn)
9.7 U.S. Asthma & COPD Therapies Market Analysis
9.8 Canada Asthma & COPD Therapies Market Analysis

10 Europe Asthma & COPD Therapies Market Analysis
10.1 Key Findings
10.2 Europe Asthma & COPD Therapies Market Attractiveness Index
10.3 Market Size by Country, 2023, 2028 & 2033 (US$ Bn)
10.4 Market Size Estimation and Forecast by Country, 2023-2033 (US$ bn)
10.5 Market Size Estimation and Forecast by Route of Administration, 2023-2033 (US$ bn)
10.6 Market Size Estimation and Forecast by Point of Sale, 2023-2033 (US$ bn)
10.7 Germany Asthma & COPD Therapies Market Analysis
10.8 UK Asthma & COPD Therapies Market Analysis
10.9 France Asthma & COPD Therapies Market Analysis
10.10 Italy Asthma & COPD Therapies Market Analysis
10.11 Spain Asthma & COPD Therapies Market Analysis
10.12 Rest of Europe Asthma & COPD Therapies Market Analysis

11 Asia Pacific Asthma & COPD Therapies Market Analysis
11.1 Key Findings
11.2 Asia Pacific Asthma & COPD Therapies Market Attractiveness Index
11.3 Market Size by Country, 2023, 2028 & 2033 (US$ Bn)
11.4 Market Size Estimation and Forecast by Country, 2023-2033 (US$ bn)
11.5 Market Size Estimation and Forecast by Route of Administration, 2023-2033 (US$ bn)
11.6 Market Size Estimation and Forecast by Point of Sale, 2023-2033 (US$ bn)
11.7 Japan Asthma & COPD Therapies Market Analysis
11.8 China Asthma & COPD Therapies Market Analysis
11.9 India Asthma & COPD Therapies Market Analysis
11.10 Australia Asthma & COPD Therapies Market Analysis
11.11 South Korea Asthma & COPD Therapies Market Analysis
11.12 Rest of Asia Pacific Asthma & COPD Therapies Market Analysis

12 Latin America Asthma & COPD Therapies Market Analysis
12.1 Key Findings
12.2 Latin America Asthma & COPD Therapies Market Attractiveness Index
12.3 Market Size by Country, 2023, 2028 & 2033 (US$ Bn)
12.4 Market Size Estimation and Forecast by Country, 2023-2033 (US$ bn)
12.5 Market Size Estimation and Forecast by Route of Administration, 2023-2033 (US$ bn)
12.6 Market Size Estimation and Forecast by Point of Sale, 2023-2033 (US$ bn)
12.7 Brazil Asthma & COPD Therapies Market Analysis
12.8 Mexico Asthma & COPD Therapies Market Analysis
12.9 Rest of Latin America Asthma & COPD Therapies Market Analysis

13 MEA Asthma & COPD Therapies Market Analysis
13.1 Key Findings
13.2 MEA Asthma & COPD Therapies Market Attractiveness Index
13.3 Market Size by Country, 2023, 2028 & 2033 (US$ Bn)
13.4 Market Size Estimation and Forecast by Country, 2023-2033 (US$ bn)
13.5 Market Size Estimation and Forecast by Route of Administration, 2023-2033 (US$ bn)
13.6 Market Size Estimation and Forecast by Point of Sale, 2023-2033 (US$ bn)
13.7 GCC Asthma & COPD Therapies Market Analysis
13.8 South Africa Asthma & COPD Therapies Market Analysis
13.9 Rest of MEA Asthma & COPD Therapies Market Analysis

14 Company Profiles
14.1 AstraZeneca
14.1.1 Company Snapshot
14.1.2 Company Overview
14.1.3 Financial Analysis
14.1.3.1 Net Revenue, 2015-2021
14.1.3.2 Regional Market Shares, 2021
14.1.3.3 Gross Profit, 2015-2021
14.1.3.4 R&D, 2015-2021
14.1.4 Product Benchmarking
14.1.5 Strategic Outlook
14.2 GSK plc
14.2.1 Company Snapshot
14.2.2 Company Overview
14.2.3 Financial Analysis
14.2.3.1 Net Revenue, 2015-2021
14.2.3.2 Regional Market Shares, 2021
14.2.3.3 Gross Profit, 2015-2021
14.2.3.4 R&D, 2015-2021
14.2.4 Product Benchmarking
14.2.5 Strategic Outlook
14.3 Boehringer Ingelheim
14.3.1 Company Snapshot
14.3.2 Company Overview
14.3.3 Financial Analysis
14.3.3.1 Net Revenue, 2015-2021
14.3.3.2 Regional Market Shares, 2021
14.3.4 Product Benchmarking
14.3.5 Strategic Outlook
14.4 Teva Pharmaceutical Industries Ltd.
14.4.1 Company Snapshot
14.4.2 Company Overview
14.4.3 Financial Analysis
14.4.3.1 Net Revenue, 2015-2021
14.4.3.2 Regional Market Shares, 2021
14.4.3.3 Gross Profit, 2015-2021
14.4.3.4 R&D, 2015-2021
14.4.4 Product Benchmarking
14.4.5 Strategic Outlook
14.5 Viatris Inc.
14.5.1 Company Snapshot
14.5.2 Company Overview
14.5.3 Financial Analysis
14.5.3.1 Net Revenue, 2015-2021
14.5.3.2 Gross Profit, 2015-2021
14.5.3.3 R&D, 2015-2021
14.5.4 Product Benchmarking
14.5.5 Strategic Outlook
14.6 F. Hoffmann-La Roche Ltd.
14.6.1 Company Snapshot
14.6.2 Company Overview
14.6.3 Financial Analysis
14.6.3.1 Net Revenue, 2015-2021
14.6.3.2 Gross Profit, 2015-2021
14.6.3.3 R&D, 2015-2021
14.6.4 Product Benchmarking
14.7 Novartis AG
14.7.1 Company Snapshot
14.7.2 Company Overview
14.7.3 Financial Analysis
14.7.3.1 Net Revenue, 2015-2021
14.7.3.2 Regional Market Shares, 2021
14.7.3.3 Gross Profit, 2015-2021
14.7.3.4 R&D, 2015-2021
14.7.4 Product Benchmarking
14.7.5 Strategic Outlook
14.8 Mundipharma
14.8.1 Company Snapshot
14.8.2 Company Overview
14.8.3 Product Benchmarking
14.9 Cipla Inc.
14.9.1 Company Snapshot
14.9.2 Company Overview
14.9.3 Financial Analysis
14.9.3.1 Net Revenue, 2015-2021
14.9.3.2 Regional Market Shares, 2021
14.9.4 Product Benchmarking
14.9.5 Strategic Outlook
14.10 Pulmatrix
14.10.1 Company Snapshot
14.10.2 Company Overview
14.10.3 Product Benchmarking
14.10.4 Strategic Outlook
14.11 TFF Pharmaceuticals, Inc.
14.11.1 Company Snapshot
14.11.2 Company Overview
14.11.3 Product Benchmarking
14.11.4 Strategic Outlook
14.12 Respiratorius AB
14.12.1 Company Snapshot
14.12.2 Company Overview
14.12.3 Product Benchmarking
14.13 Chiesi Farmaceutici S.p.A.
14.13.1 Company Snapshot
14.13.2 Company Overview
14.13.3 Product Benchmarking
14.14 Grifols S.A.
14.14.1 Company Snapshot
14.14.2 Company Overview
14.14.3 Financial Analysis
14.14.3.1 Net Revenue, 2015-2021
14.14.3.2 Regional Market Shares, 2021
14.14.3.3 Gross Profit, 2015-2021
14.14.3.4 R&D, 2015-2021
14.14.4 Product Benchmarking
14.14.5 Strategic Outlook
14.15 Sanofi SA
14.15.1 Company Snapshot
14.15.2 Company Overview
14.15.3 Financial Analysis
14.15.3.1 Net Revenue, 2015-2021
14.15.3.2 Regional Market Shares, 2021
14.15.3.3 Gross Profit, 2015-2021
14.15.3.4 R&D, 2015-2021
14.15.4 Product Benchmarking
14.15.5 Strategic Outlook
14.16 Sunovion Pharmaceuticals Inc.
14.16.1 Company Snapshot
14.16.2 Company Overview
14.16.3 Product Benchmarking
14.17 Transpire Bio
14.17.1 Company Snapshot
14.17.2 Company Overview
14.17.3 Product Benchmarking
14.18 Verona Pharma plc
14.18.1 Company Snapshot
14.18.2 Company Overview
14.18.3 Product Benchmarking
14.18.4 Strategic Outlook

15 Conclusion and Recommendations
15.1 Concluding Remarks from
15.2 Recommendations for Market Players



★調査レポート[世界の喘息＆COPD治療市場2023年～2033年] (コード：VGA23FB019)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の喘息＆COPD治療市場2023年～2033年]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 世界の喘息＆COPD治療薬市場2023-2030：疾患別（喘息、COPD）、薬効分類別（配合剤、短時間作用型β作動薬（SABA）、長時間作用型β作動薬（LABA）、ロイコトリエン拮抗薬（LTA）、抗コリン薬、その他）、地域別
  • 世界の髄膜炎菌ワクチン市場2023年～2033年
  • 世界の抗生物質市場2023年～2033年
  • 世界の呼吸器用吸入器市場2023年～2033年
  • 世界の心血管装置市場2023年～2033年
  • 世界のバイオディフェンス市場2023年～2033年
  • 世界のニューロテックデバイス市場2023年～2033年
  • 世界のPoC診断市場2023年～2033年
  • 世界の神経刺激装置市場2023年～2033年

    • ◆H&Iグローバルリサーチのお客様（例）◆